AVRO تصريحات هيئة الأوراق المالية والبورصات - AVROBIO, Inc.- التقرير السنوي، بيان التوكيل، نشرة الإصدار

الإحصائيات الأساسية

CIK

1681087

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to AVROBIO, Inc.

SEC Filings (Chronological Order)

توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.

August 7, 2025	EX-99.2	Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes, EX-99.2 AUGUST 2025 Innovating GPCR-Targeted Therapies to Reach Large Untapped Market Opportunities Exhibit 99.2 Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," “plans,” “pot
August 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38537 TECTONIC THERAPEUTIC, INC.
August 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Tectonic Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Tectonic Therapeutic, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38537 81-0710585 (State or Other Jurisdiction of Incorporation) (Commissi
August 7, 2025	EX-99.1	Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights EX-99.1 Exhibit 99.1 Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights • TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45’s safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease (“PH-ILD”, Group 3 PH) to expand the therapeutic breadth of TX45 • Complete res
July 15, 2025	424B3	Up to $100,000,000 Common Stock Table of Contents As Filed Pursuant to Rule 424(b)(3) Registration No. 333-288539 PROSPECTUS SUPPLEMENT (To Prospectus dated July 15, 2025) Up to $100,000,000 Common Stock We have entered into a sales agreement with TD Securities (USA) LLC (“TD Cowen”), dated as of July 7, 2025 (the “sales agreement”), relating to the sale of shares of our common stock, par value $0.0001 per share (the “common sto
July 11, 2025	CORRESP	TECTONIC THERAPEUTIC, INC. 490 Arsenal Way, Suite 210 Watertown, MA 02472 (339) 666-3320 CORRESP TECTONIC THERAPEUTIC, INC. 490 Arsenal Way, Suite 210 Watertown, MA 02472 (339) 666-3320 July 11, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Information Technologies and Services 100 F Street, N.E. Washington, D.C. 20549 Re: Tectonic Therapeutic, Inc. Registration Statement on Form S-3 File No. 333-288539 Ladies and Gentlemen: In accord
July 7, 2025	EX-4.8	Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.8 Exhibit 4.8 TECTONIC THERAPEUTIC, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF TECTONIC THERAPEUTIC, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between TECTONIC THERAPEUTIC, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association
July 7, 2025	POS AM	As filed with the Securities and Exchange Commission on July 7, 2025 POS AM Table of Contents As filed with the Securities and Exchange Commission on July 7, 2025 Registration No.
July 7, 2025	EX-FILING FEES	Filing Fee Table. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Tectonic Therapeutic, Inc.
July 7, 2025	EX-4.10	Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.10 Exhibit 4.10 TECTONIC THERAPEUTIC, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF TECTONIC THERAPEUTIC, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between TECTONIC THERAPEUTIC, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association
July 7, 2025	EX-4.5	Form of Indenture. EX-4.5 Exhibit 4.5 TECTONIC THERAPEUTIC, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certifi
July 7, 2025	S-3	As filed with the Securities and Exchange Commission on July 7, 2025 Table of Contents As filed with the Securities and Exchange Commission on July 7, 2025 Registration No.
July 7, 2025	POS AM	As filed with the Securities and Exchange Commission on July 7, 2025 POS AM Table of Contents As filed with the Securities and Exchange Commission on July 7, 2025 Registration No.
July 7, 2025	EX-4.9	Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.9 Exhibit 4.9 TECTONIC THERAPEUTIC, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF TECTONIC THERAPEUTIC, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between TECTONIC THERAPEUTIC, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association]
July 7, 2025	EX-1.2	Sales Agreement, by and between the Registrant and TD Securities (USA) LLC, dated July 7, 2025. Exhibit 1.2 TECTONIC THERAPEUTIC, INC. COMMON STOCK SALES AGREEMENT July 7, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Tectonic Therapeutic, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from t
June 11, 2025	424B5	Tectonic Therapeutic, Inc. Up to 3,689,465 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-286133 PROSPECTUS SUPPLEMENT (To Prospectus dated April 2, 2025) Tectonic Therapeutic, Inc. Up to 3,689,465 Shares of Common Stock This prospectus supplement supplements the prospectus dated April 2, 2025 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-286133). This prospectus supplement is being filed
June 11, 2025	424B5	Tectonic Therapeutic, Inc. Up to 2,969,583 Shares of Common Stock 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-280909 PROSPECTUS SUPPLEMENT (To Prospectus dated April 3, 2025) Tectonic Therapeutic, Inc. Up to 2,969,583 Shares of Common Stock This prospectus supplement supplements the prospectus dated April 3, 2025 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280909), as amended. This prospectus suppleme
June 6, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2025 Tectonic Therapeutic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission
May 19, 2025	424B5	Tectonic Therapeutic, Inc. Up to 2,969,583 Shares of Common Stock 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-280909 PROSPECTUS SUPPLEMENT (To Prospectus dated April 3, 2025) Tectonic Therapeutic, Inc. Up to 2,969,583 Shares of Common Stock This prospectus supplement supplements the prospectus dated April 3, 2025 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280909), as amended. This prospectus suppleme
May 19, 2025	EX-99.1	Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025 Exhibit 99.1 Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025 • Data confirmed TX45’s tolerability profile and improved left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with p
May 19, 2025	424B5	Tectonic Therapeutic, Inc. Up to 3,689,465 Shares of Common Stock 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-286133 PROSPECTUS SUPPLEMENT (To Prospectus dated April 2, 2025) Tectonic Therapeutic, Inc. Up to 3,689,465 Shares of Common Stock This prospectus supplement supplements the prospectus dated April 2, 2025 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-286133). This prospectus supplement is being
May 19, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2025 Tectonic Therapeutic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (state or other jurisdiction of incorporation) (Commission
May 8, 2025	424B3	Tectonic Therapeutic, Inc. Up to 3,689,465 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-286133 PROSPECTUS SUPPLEMENT (To Prospectus dated April 2, 2025) Tectonic Therapeutic, Inc. Up to 3,689,465 Shares of Common Stock This prospectus supplement supplements the prospectus dated April 2, 2025 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-286133). This prospectus su
May 8, 2025	EX-99.1	Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights Exhibit 99.1 Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights • Interim analysis from the TX45 Phase 1b Part A trial demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) • Full results from the
May 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38537 TECTONIC THERAPEUTIC, INC.
May 8, 2025	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 Tectonic Therapeutic, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38537 81-0710585 (State or Other Jurisdiction of Incorporation) (Commission
May 8, 2025	424B3	Tectonic Therapeutic, Inc. Up to 2,969,583 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-280909 PROSPECTUS SUPPLEMENT (To Prospectus dated April 3, 2025) Tectonic Therapeutic, Inc. Up to 2,969,583 Shares of Common Stock This prospectus supplement supplements the prospectus dated April 3, 2025 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280909), as amended. This prospec
April 25, 2025	DEFA14A	SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material under § 240.
April 25, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a
March 31, 2025	CORRESP	TECTONIC THERAPEUTIC, INC. 490 Arsenal Way, Suite 210 Watertown, MA 02472 (339) 666-3320 CORRESP TECTONIC THERAPEUTIC, INC. 490 Arsenal Way, Suite 210 Watertown, MA 02472 (339) 666-3320 March 31, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Information Technologies and Services 100 F Street, N.E. Washington, D.C. 20549 Re: Tectonic Therapeutic, Inc. Registration Statement on Form S-1 File No. 333-286133 Ladies and Gentlemen: In accor
March 27, 2025	POS AM	As filed with the Securities and Exchange Commission on March 26, 2025 Registration No. 333-280909 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SEC Table of Contents As filed with the Securities and Exchange Commission on March 26, 2025 Registration No.
March 26, 2025	S-1	As filed with the Securities and Exchange Commission on March 26, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tectonic Therap Table of Contents As filed with the Securities and Exchange Commission on March 26, 2025 Registration No.
March 26, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Tectonic Therapeutic, Inc.
March 26, 2025	EX-21.1	List of Subsidiaries Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of incorporation or organization AVROBIO Inc. Ontario, Canada AVROBIO Australia Pty Ltd Australia AVROBIO Securities Corporation Massachusetts Tectonic Therapeutic Pty Ltd. Australia Tectonic Therapeutic Securities Corp. Massachusetts Tectonic Operating Company, Inc. Delaware
March 20, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 Tectonic Therapeutic, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38537 81-0710585 (State or Other Jurisdiction of Incorporation) (Commissi
March 20, 2025	EX-4.1	Description of Capital Stock. Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK The following description of our capital stock and provisions of our charter and bylaws are summaries and are qualified by reference to such charter and bylaws and applicable provisions of Delaware corporate law. You should read our certificate of incorporation and our bylaws, in each case, as amended and supplemented, each of which is filed as an exhibit t
March 20, 2025	EX-19.1	Insider Trading Policy of Tectonic Therapeutic, Inc. Exhibit 19.1 TECTONIC THERAPEUTIC, INC. Insider Trading Policy (adopted June 18, 2024) Introduction During the course of your relationship with Tectonic Therapeutic, Inc. (“Tectonic”), you may receive material information that is not yet publicly available (“material nonpublic information”) about Tectonic or other publicly traded companies. Material nonpublic information may give you, or someone y
March 20, 2025	EX-21.1	List of Subsidiaries. Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of incorporation or organization AVROBIO Inc. Ontario, Canada AVROBIO Australia Pty Ltd Australia AVROBIO Securities Corporation Massachusetts Tectonic Therapeutic Pty Ltd. Australia Tectonic Therapeutic Securities Corp. Massachusetts Tectonic Operating Company, Inc. Delaware
March 20, 2025	EX-99.1	Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights Exhibit 99.1 Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights • TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) • Positive TX45 Phase 1b
March 20, 2025	S-8	As filed with the Securities and Exchange Commission on March 20, 2025 As filed with the Securities and Exchange Commission on March 20, 2025 Registration No.
March 20, 2025	EX-10.17	Offer Letter dated May 28, 2025, by and between Tectonic Therapeutic, Inc. and Daniel Lochner. Exhibit 10.17 Date: May 28, 2024 Name: Daniel (Dan) Lochner Via Electronic Delivery Dear Dan, It is with great pleasure that I am inviting you to join our team at Tectonic Therapeutic, Inc. (the “Company”). Your position will be that of Chief Financial Officer (“Role”). Your employment with the Company in the Role will commence as of June 3, 2024, or on such other date as determined by you and the
March 20, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Tectonic Therapeutic, Inc.
March 20, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38537 TECTONIC THERA
March 20, 2025	EX-97.1	Incentive Compensation Recoupment Policy of Tectonic Therapeutic, Inc. Exhibit 97.1 TECTONIC THERAPEUTIC, INC. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of TECTONIC THERAPEUTIC, INC., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Po
February 12, 2025	424B5	Tectonic Therapeutic, Inc. Up to 2,969,583 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-280909 PROSPECTUS SUPPLEMENT (To Prospectus dated July 30, 2024) Tectonic Therapeutic, Inc. Up to 2,969,583 Shares of Common Stock This prospectus supplement supplements the prospectus dated July 30, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280909). This prospectus supplement is being filed
February 12, 2025	424B3	Tectonic Therapeutic, Inc. Up to 2,969,583 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-280909 PROSPECTUS SUPPLEMENT (To the Prospectus dated July 30, 2024) Tectonic Therapeutic, Inc. Up to 2,969,583 Shares of Common Stock This prospectus supplement supplements the prospectus, dated July 30, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280909). This prospectus sup
February 12, 2025	424B5	Tectonic Therapeutic, Inc. Up to 2,969,583 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-280909 PROSPECTUS SUPPLEMENT (To Prospectus dated July 30, 2024) Tectonic Therapeutic, Inc. Up to 2,969,583 Shares of Common Stock This prospectus supplement supplements the prospectus dated July 30, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280909). This prospectus supplement is being filed
February 3, 2025	EX-10.1	Form of Securities Purchase Agreement Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of February 3, 2025, by and among Tectonic Therapeutic, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and
February 3, 2025	EX-10.2	Form of Registration Rights Agreement Exhibit 10.2 FORM OF REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 3, 2025, is entered into by and among Tectonic Therapeutic, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitali
February 3, 2025	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2025 TECTONIC THERAPEUTIC, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation or organ
February 3, 2025	EX-99.1	Tectonic Announces $185 Million Private Placement Exhibit 99.1 Tectonic Announces $185 Million Private Placement WATERTOWN, Mass., February 3, 2025 – Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced that it has entered into a securities purchase agreement for a private investment in public equity financing (the “PIPE”) that is expected to result in gross proceeds of approximately $185.0 million. Pursuant to the terms of the
January 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2025 Tectonic Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2025 Tectonic Therapeutic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (state or other jurisdiction of incorporation) (Commis
January 30, 2025	EX-99.2	Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF Exhibit 99.2 Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF • TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), supporting endpoints and patient populations in ongoing APEX P
January 30, 2025	EX-99.1	2 DISCLAIMER Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as anticipates, Exhibit 99.1 TX45 Phase 1b PH-HFpEF Interim Data Release for Single Dose Hemodynamic Trial January 2025 2 DISCLAIMER Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as anticipates, believes, expects, intends, “plans,” “potenti
January 13, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Tectonic Therapeutic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (state or other jurisdiction of incorporation) (Commis
January 13, 2025	EX-99.1	2 DISCLAIMER Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as anticipates, Exhibit 99.1 Innovating GPCR-Targeted Therapies to Reach Large Untapped Market Opportunities JANUARY 2025 2 DISCLAIMER Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as anticipates, believes, expects, intends, “plans,” “poten
November 14, 2024	SC 13G/A	TECX / Tectonic Therapeutic, Inc. / Newtyn Management, LLC Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TECTONIC THERAPEUTIC, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 878972108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the a
November 12, 2024	EX-10.1	Non-Employee Director Compensation Policy of Tectonic Therapeutic, Inc. Exhibit 10.1 Tectonic Therapeutic, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of Tectonic Therapeutic, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (the “Policy”) for his or her Board se
November 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38537 TECTONIC THERAPEUTIC, INC.
November 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2024 Tectonic Therapeutic, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38537 81-0710585 (State or Other Jurisdiction of Incorporation) (Commi
November 7, 2024	EX-99.1	Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights Exhibit 99.1 Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights • Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1’2025 or early Q2’2025 • First subject dosed with TX000045 (“TX45”) in APEX Phase 2 clinical trial in early October, with topline results expected in 2026 • De
October 28, 2024	SC 13D/A	TECX / Tectonic Therapeutic, Inc. / Atlas Venture Fund X, L.P. - SC 13D/A Activist Investment SC 13D/A 1 tm2426988d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tectonic Therapeutic, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 878972108 (CUSIP Number) Atlas Venture Attention: Ommer Chohan, Chief Financial Officer 300 Tec
October 24, 2024	SC 13D/A	TECX / Tectonic Therapeutic, Inc. / SPRINGER TIMOTHY A - AMENDMENT NO. 2 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Tectonic Therapeutic, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 878972108 (CUSIP Number) Michael K. Bradshaw, Jr. Nelson Mullins Riley & Scarborough LLP 101 Constitution Avenue NW, Suite 900 Washington
September 26, 2024	SC 13D/A	TECX / Tectonic Therapeutic, Inc. / SPRINGER TIMOTHY A - AMENDMENT NO. 1 TO SCHEDULE 13D Activist Investment SC 13D/A 1 ea0215858-13da1springertect.htm AMENDMENT NO. 1 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tectonic Therapeutic, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 878972108 (CUSIP Number) Michael K. Bradshaw, Jr. Nelson Mulli
September 26, 2024	EX-99.4	Joint Filing Agreement, filed herewith. EX-99.4 2 ea021585801ex99-4tect.htm JOINT FILING AGREEMENT, FILED HEREWITH Exhibit 99.4 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree, as of September 26, 2024, that only one statement containing the information required by Schedule 13D, and each amendment thereto, need be filed with respect to the ownership
September 26, 2024	EX-99.5	Stock Transfer Agreement, dated as of September 24, 2024 by and among TAS Partners, LLC, Timothy Springer and Chafen Lu, filed herewith EX-99.5 3 ea021585801ex99-5tect.htm STOCK TRANSFER AGREEMENT, DATED AS OF SEPTEMBER 24, 2024 BY AND AMONG TAS PARTNERS, LLC, TIMOTHY SPRINGER AND CHAFEN LU, FILED HEREWITH Exhibit 99.5 TECTONIC THERAPEUTIC, INC. STOCK TRANSFER AGREEMENT THIS STOCK TRANSFER AGREEMENT (this “Agreement”) is made and entered into on September 24, 2024, (the “Effective Date”) by and between TAS Partners, LLC (the “Tran
September 19, 2024	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2024 TECTONIC THERAPEUTIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Comm
September 19, 2024	EX-99.2	DISCLAIMER Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as anticipates, b Exhibit 99.2 Transforming and Innovating the Discovery and Development of Novel, Class Leading GPCR-Targeted Therapies S e p t e m b e r 2 0 2 4 DISCLAIMER Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as anticipates, believ
September 19, 2024	EX-99.1	Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45 TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses f Exhibit 99.1 Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45 TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the Phase 2 clinical trial Results to be presented at the American Heart Association (AHA) Scientific Sessions in November 2024 Phase
August 27, 2024	S-8 POS	As filed with the Securities and Exchange Commission on August 27, 2024 As filed with the Securities and Exchange Commission on August 27, 2024 Registration No.
August 21, 2024	S-8	As filed with the Securities and Exchange Commission on August 21, 2024 S-8 As filed with the Securities and Exchange Commission on August 21, 2024 Registration No.
August 21, 2024	EX-FILING FEES	Filing Fee Table. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Tectonic Therapeutic, Inc.
August 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT P Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38537 TECTONIC THERAPEUTIC, INC.
August 14, 2024	EX-99.1	Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights EX-99.1 Exhibit 99.1 Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights • TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024 • Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024 • Completed reverse merger with AVROBIO in June
August 14, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 Tectonic Therapeutic, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38537 81-0710585 (State or Other Jurisdiction of Incorporation) (Commiss
August 14, 2024	424B3	Up to 2,969,583 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-280909 PROSPECTUS SUPPLEMENT (To the Prospectus dated July 30, 2024) Up to 2,969,583 Shares of Common Stock This prospectus supplement supplements the prospectus, dated July 30, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280909). This prospectus supplement is being filed to u
August 14, 2024	EX-3.1	Fourth Amended and Restated Certificate of Incorporation, as amended through June 20, 2024. EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AVROBIO, INC. AVROBIO, Inc. (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware, does hereby certify as follows: 1. That the Fourth Amended and Restated Certificate of Incorporation of the Corporation that was filed with the Secretary of State
July 31, 2024	424B5	Tectonic Therapeutic, Inc. Up to 2,969,583 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-280909 PROSPECTUS SUPPLEMENT (To Prospectus dated July 30, 2024) Tectonic Therapeutic, Inc. Up to 2,969,583 Shares of Common Stock This prospectus supplement supplements the prospectus dated July 30, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280909). This prospectus supplement is being filed
July 30, 2024	424B3	Up to 2,969,583 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-280909 PROSPECTUS Up to 2,969,583 Shares of Common Stock This prospectus relates to the proposed offer and resale or other disposition from time to time by the selling stockholders identified in this prospectus of up to an aggregate of 2,969,583 shares of common stock, par value $0.0001 per share, of Tectonic Therapeutic, Inc.
July 30, 2024	EX-99.1	Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45 EX-99.1 Exhibit 99.1 Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45 • TX45 is an Fc-relaxin fusion protein being evaluated in patients with Group 2 Pulmonary Hypertension (PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF), a serious condition estimated to affect over 600,000 people in the U.S. alone, currently with no approved therapies • Planned initiation
July 30, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 TECTONIC THERAPEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 TECTONIC THERAPEUTIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commissio
July 30, 2024	EX-99.2	DISCLAIMER Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as anticipates, b EX-99.2 Exhibit 99.2 Transforming and Innovating the Discovery and Development of Novel, Class Leading GPCR-Targeted Therapies J u l y 2 0 2 4 DISCLAIMER Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as anticipates, believes
July 26, 2024	CORRESP	TECTONIC THERAPEUTIC, INC. 490 Arsenal Way, Suite 210 Watertown, MA 02472 (339) 666-3320 TECTONIC THERAPEUTIC, INC. 490 Arsenal Way, Suite 210 Watertown, MA 02472 (339) 666-3320 July 26, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Information Technologies and Services 100 F Street, N.E. Washington, D.C. 20549 Re: Tectonic Therapeutic, Inc. Registration Statement on Form S-1 File No. 333-280909 Ladies and Gentlemen: In accordance wit
July 19, 2024	S-1	Power of Attorney (included on signature page). Table of Contents As filed with the Securities and Exchange Commission on July 19, 2024 Registration No .
July 19, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Tectonic Therapeutic, Inc.
July 19, 2024	EX-21.1	List of Subsidiaries Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of incorporation or organization AVROBIO Inc. Ontario, Canada AVROBIO Australia Pty Ltd Australia AVROBIO Securities Corporation Massachusetts Tectonic Therapeutic Pty Ltd. Australia Tectonic Therapeutic Securities Corp. Massachusetts Tectonic Operating Company, Inc. Delaware
July 5, 2024	EX-10.1	Separation Agreement, dated as of July 5, 2024, by and among Tectonic Therapeutic, Inc. and Christian Cortis EX-10.1 Exhibit 10.1 June 7, 2024 Christian Cortis 1 Sylvan Road Wellesley, MA 02481 Via Electronic Delivery Dear Chris: This letter is to summarize the terms of the separation package that Tectonic Therapeutic, Inc. (the “Company”) is willing to offer you. Please read this letter agreement (the “Letter Agreement”), which includes a general release, carefully. If you are willing to agree to its te
July 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 28, 2024 TECTONIC THERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 28, 2024 TECTONIC THERAPEUTIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission
July 1, 2024	SC 13G	AVRO / AVROBIO, Inc. / EcoR1 Capital, LLC Passive Investment SC 13G 1 tecx13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tectonic Therapeutic, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 878972108 (CUSIP Number) June 20, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate
June 27, 2024	SC 13D	AVRO / AVROBIO, Inc. / Vida Ventures II, LLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Tectonic Therapeutic, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 878972 108 (CUSIP Number) Jean-Philippe Kouakou-Zebouah Chief Financial Officer Vida Ventures II, LLC 40 Broad Street, Suite 201 Boston, M
June 26, 2024	EX-99.1	Transforming and Innovating the Discovery and Development of Novel, Class Leading GPCR-Targeted TherapiesJ u n e 2 0 2 4 EX-99.1 Exhibit 99.1 Transforming and Innovating the Discovery and Development of Novel, Class Leading GPCR-Targeted TherapiesJ u n e 2 0 2 4 Transforming and Innovating the Discovery and Development of Novel, Class Leading GPCR-Targeted TherapiesJ u n e 2 0 2 4DISCLAIMERStatements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” withi
June 26, 2024	EX-99.3	Joint Filing Agreement, filed herewith. EX-99.3 2 ea020848301ex99-3tect.htm JOINT FILING AGREEMENT Exhibit 99.3 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree, as of June 26, 2024, that only one statement containing the information required by Schedule 13D, and each amendment thereto, need be filed with respect to the ownership by each of the unders
June 26, 2024	SC 13D	AVRO / AVROBIO, Inc. / SPRINGER TIMOTHY A - SCHEDULE 13D Activist Investment SC 13D 1 ea0208483-13dspringertect.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Tectonic Therapeutic, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 878972108 (CUSIP Number) Michael K. Bradshaw, Jr. Nelson Mullins Riley & Scarborough L
June 26, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 25, 2024 TECTONIC THERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 25, 2024 TECTONIC THERAPEUTIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission
June 25, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 d780356dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that
June 25, 2024	SC 13D	AVRO / AVROBIO, Inc. / MCGUIRE TERRANCE - SC 13D Activist Investment SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) TECTONIC THERAPEUTIC, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 878972108 (CUSIP Number) Lauren Crockett Polaris Partners One Marina Park Drive, 8th Floor Boston, MA 02210 (781) 290-0770 (Name, Address and Telephone Numb
June 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 Tectonic Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 Tectonic Therapeutic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commissio
June 20, 2024	EX-10.1	Contingent Value Rights Agreement dated June 20, 2024, by and between Tectonic Therapeutic, Inc. and Computershare Trust Company, LLC. Exhibit 10.1 CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of June 20, 2024, is entered into by and among AVROBIO, Inc., a Delaware corporation (the “Company”) and Computershare Inc., a Delaware corporation, (“Computershare”) and its affiliate Computershare Trust Company, N.A., a federally chartered trust company, jointly as rights agent (col
June 20, 2024	EX-10.3	Subscription Agreement, dated as of January 29, 2024, by and among Tectonic Therapeutic, Inc. and the purchasers thereunder Exhibit 10.3 SUBSCRIPTION AGREEMENT THIS SUBSCRIPTION AGREEMENT (this “Agreement”), is made as of January 29, 2024 (the “Effective Date”), by and between Tectonic Therapeutic, Inc., a Delaware corporation (the “Company”) and each of the investors listed on Exhibit A attached to this Agreement (each a “Purchaser” and together the “Purchasers”). RECITALS WHEREAS, the Company and the Purchasers are e
June 20, 2024	EX-10.8	Tectonic Therapeutic, Inc. 2024 Employee Stock Purchase Plan. Exhibit 10.8 TECTONIC THERAPEUTIC, INC. 2024 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE 20, 2024 APPROVED BY THE STOCKHOLDERS: JUNE 11, 2024 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a se
June 20, 2024	EX-10.6	Tectonic Therapeutic, Inc. 2024 Equity Incentive Plan. Exhibit 10.6 TECTONIC THERAPEUTIC, INC. 2024 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE 20, 2024 APPROVED BY THE STOCKHOLDERS: JUNE 11, 2024 1. GENERAL. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company
June 20, 2024	EX-10.2	Form of Indemnification Agreement between Tectonic Therapeutic, Inc. and each of its directors and executive officers. Exhibit 10.2 TECTONIC THERAPEUTIC, INC. FORM OF INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , 2024, is made by and between TECTONIC THERAPEUTIC, INC., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS A. The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents. B. The Compa
June 20, 2024	EX-99.2	TECTONIC MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 TECTONIC MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of Tectonic’s financial condition and results of operations together with Tectonic’s unaudited consolidated financial statements and the related notes included as Exhibit 99.3 to this Current Report on Form 8-K. This discussion and analys
June 20, 2024	EX-10.4	Amended and Restated Employment Agreement, dated as of June 20, 2024, by and between Tectonic Therapeutic, Inc. and Alise Reicin, M.D. Exhibit 10.4 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of June 20, 2024, by and between Tectonic Therapeutic, Inc. (the “Company”), and Alise Reicin (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Company and Executive are pa
June 20, 2024	EX-10.7	Forms of Option Grant Notice, Option Agreement and Notice of Exercise under Tectonic Therapeutic, Inc. 2024 Equity Incentive Plan. Exhibit 10.7 TECTONIC THERAPEUTIC, INC. STOCK OPTION GRANT NOTICE (2024 EQUITY INCENTIVE PLAN) Tectonic Therapeutic, Inc. (the “Company”) has granted to you (the “Optionholder”) an option to purchase the number of shares of Common Stock set forth below (the “Option”) under the Tectonic Therapeutic, Inc. 2024 Equity Incentive Plan (the “Plan”). The Option is subject to all of the terms and conditio
June 20, 2024	EX-99.3	TECTONIC THERAPEUTIC, INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) March 31, 2024 December 31, 2023 (unaudited) Assets Current assets: Cash and cash equivalents $ 18,748 $ 28,769 Prepaid expe Exhibit 99.3 Page Unaudited Interim Condensed Consolidated Financial Statements for the Three Months ended March 31, 2024 and 2023 Unaudited Condensed Consolidated Balance Sheets F-2 Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss F-3 Unaudited Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Deficit F-4 Unaudited Condensed C
June 20, 2024	EX-3.2	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company, dated June 20, 2024 (Exculpation Amendment). Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AVROBIO, INC. AVROBIO, Inc. (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware, does hereby certify as follows: 1. That the Fourth Amended and Restated Certificate of Incorporation of the Corporation that was filed with the Secretary of State of Del
June 20, 2024	EX-3.3	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company, dated June 20, 2024 (Name Change Amendment). Exhibit 3.3 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AVROBIO, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware AVROBIO, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. Article I of the Fourth Amended and Restated Certificate of Incorporation of the
June 20, 2024	EX-3.1	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company, dated June 20, 2024 (Stock Split Amendment). Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AVROBIO, INC. AVROBIO, Inc. (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware, does hereby certify as follows: 1. That the Fourth Amended and Restated Certificate of Incorporation of the Corporation that was filed with the Secretary of State of Del
June 20, 2024	EX-99.1	Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million Exhibit 99.1 Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million — Tectonic will be focused on advancing a pipeline of novel G-protein-coupled receptor (“GPCR”) targeted biologic therapies, including the lead program, TX45, a Fc-relaxin fusion — TX45 is currently being evaluated in Phase 1a/1b clinical trials as a potential treatm
June 20, 2024	EX-16.1	Letter from Ernst & Young LLP dated June 20, 2024. Exhibit 16.1 June 20, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated June 20, 2024, of Tectonic Therapeutic, Inc. and are in agreement with the statements contained in the first and second sentences of the first paragraph and the second and third paragraphs under (a) Dismissal of Independent Registered Public
June 20, 2024	EX-99.4	UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.4 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On June 20, 2024, AVROBIO, Inc. (“AVROBIO”), Tectonic Therapeutic, Inc. (“Tectonic”), and AVROBIO Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (“Merger Sub”) consummated the previously announced merger transaction pursuant to that certain agreement and plan of merger and reorganization (the “Merger A
June 18, 2024	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 AVROBIO, Inc. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 AVROBIO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Numb
June 14, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 AVROBIO, Inc. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 AVROBIO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Number
June 11, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 AVROBIO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Number
June 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 AVROBIO, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 AVROBIO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Number)
June 4, 2024	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 AVROBIO, Inc. (Exact 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 AVROBIO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Num
June 3, 2024	425	Filed by AVROBIO, Inc. 425 Filed by AVROBIO, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Deemed filed pursuant to Rule 14a-6(b) under the Securities Exchange Act of 1934 Subject Company: Tectonic Therapeutic, Inc. Commission File No.: 001-38537 Date: June 3, 2024 This filing relates to the proposed transaction pursuant to the terms of that certain Agreement and Plan of Merger and Reorganization, dated as
May 28, 2024	425	REMEMBER: You can vote your shares online or by telephone. Please use the control number found on the enclosed proxy card and visit www.proxyvote.com to submit your instructions online; or if you received this letter by email, you may simply click th 425 Filed by AVROBIO, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Deemed filed pursuant to Rule 14a-6(b) under the Securities Exchange Act of 1934 Subject Company: AVROBIO, Inc. Commission File No.: 001-38537 Date: May 28, 2024 This filing relates to the proposed transaction pursuant to the terms of that certain Agreement and Plan of Merger and Reorganization, dated as of January 30
May 21, 2024	SC 13G/A	AVRO / AVROBIO, Inc. / BML Investment Partners, L.P. Passive Investment SC 13G/A 1 avro13g020724.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 2 )* AVROBIO, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05455M100 (CUSIP N
May 21, 2024	425	REMEMBER: You can vote your shares online or by telephone. Please use the control number found on the enclosed proxy card and visit www.proxyvote.com to submit your instructions online; or if you received this letter by email, you may simply click th 425 Filed by AVROBIO, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Deemed filed pursuant to Rule 14a-6(b) under the Securities Exchange Act of 1934 Subject Company: AVROBIO, Inc. Commission File No.: 001-38537 Date: May 21, 2024 This filing relates to the proposed transaction pursuant to the terms of that certain Agreement and Plan of Merger and Reorganization, dated as of January 30
May 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38537 AVROBIO, INC.
May 3, 2024	424B3	PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-277048 PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT To the Stockholders of AVROBIO, Inc. and Tectonic Therapeutic, Inc., AVROBIO, Inc., a Delaware corporation (“AVROBIO”), and Tectonic Therapeutic, Inc., a Delaware corporation (“Tectonic”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agree
May 2, 2024	CORRESP	AVROBIO, Inc. One Broadway 14th Floor Cambridge, MA 02142 AVROBIO, Inc. One Broadway 14th Floor Cambridge, MA 02142 May 2, 2024 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3628 Attention: Jenn Do, Mary Mast, Lauren Hamill and Chris Edwards Re: AVROBIO, Inc. Acceleration Request for Registration Statement on Form S-4 File No. 333-2
April 29, 2024	EX-99.10	Consent of Houlihan Lokey Capital, Inc. Exhibit 99.10 CONSENT OF HOULIHAN LOKEY CAPITAL, INC. April 29, 2024 AVROBIO, Inc. One Broadway 14th Floor Cambridge, MA 02142 Attn: Board of Directors RE: Proxy Statement / Prospectus of AVROBIO, Inc. (“AVROBIO”), which forms part of Amendment No. 3 to the Registration Statement on Form S-4 of AVROBIO (the “Registration Statement”). Dear Members of the Board: Reference is made to our opinion lett
April 29, 2024	CORRESP	***** Goodwin Procter LLP 100 Northern Avenue Boston, Massachusetts 02210 VIA EDGAR April 29, 2024 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
April 29, 2024	S-4/A	As filed with the Securities and Exchange Commission on April 29 , 2024 Registration No. 333-277048 UNITED S TATES SECURITIES AND EXCHANGE COM M ISSION Washington, D.C. 20549 AMENDMENT NO. 3 to FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT As filed with the Securities and Exchange Commission on April 29 , 2024 Registration No.
April 15, 2024	EX-10.42	Form of Amended and Restated Executive Employment Agreement, by and between Tectonic Therapeutic, Inc. and Alise Reicin. Exhibit 10.42 FORM OF AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of April [•], 2024, by and between Tectonic Therapeutic, Inc. (the “Company”), and Alise Reicin (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Company and Execu
April 15, 2024	EX-99.3	Consent of Terrance McGuire to serve as a director of AVROBIO, Inc., to be renamed “Tectonic Therapeutic, Inc.” Exhibit 99.3 Consent to be Named as a Director In connection with the filing by AVROBIO, Inc. (the “Company”) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments a
April 15, 2024	EX-99.5	Consent of Praveen Tipirneni to serve as a director of AVROBIO, Inc., to be renamed “Tectonic Therapeutic, Inc.” Exhibit 99.5 Consent to be Named as a Director In connection with the filing by AVROBIO, Inc. (the “Company”) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments a
April 15, 2024	EX-99.7	Consent of Alise Reicin to serve as a director of AVROBIO, Inc., to be renamed “Tectonic Therapeutic, Inc.” Exhibit 99.7 Consent to be Named as a Director In connection with the filing by AVROBIO, Inc. (the “Company”) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments a
April 15, 2024	EX-99.4	Consent of Timothy A. Springer to serve as a director of AVROBIO, Inc., to be renamed “Tectonic Therapeutic, Inc.” Exhibit 99.4 Consent to be Named as a Director In connection with the filing by AVROBIO, Inc. (the “Company”) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments a
April 15, 2024	EX-10.47	Form of Severance Plan and Form of Participation Agreement of Tectonic Therapeutic, Inc. Exhibit 10.47 TECTONIC THERAPEUTIC, INC. SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION APPROVED BY THE BOARD OF DIRECTORS: , 2024 1. Introduction. The purpose of this Tectonic Therapeutic, Inc. Severance Plan (the “Plan”) is to provide assurances of specified severance benefits to eligible executives of the Company whose employment is terminated by the Company or a successor under certain circums
April 15, 2024	EX-99.10	Consent of Houlihan Lokey Capital, Inc. Exhibit 99.10 CONSENT OF HOULIHAN LOKEY CAPITAL, INC. April 15, 2024 AVROBIO, Inc. 100 Technology Square 6th Floor Cambridge, MA 02139 Attn: Board of Directors RE: Proxy Statement / Prospectus of AVROBIO, Inc. (“AVROBIO”), which forms part of Amendment No. 2 to the Registration Statement on Form S-4 of AVROBIO (the “Registration Statement”). Dear Members of the Board: Reference is made to our opin
April 15, 2024	S-4/A	As filed with the Securities and Exchange Commission on April 1 5 , 2024 Registration No. 333-277048 UNITED S TATES SECURITIES AND EXCHANGE COM M ISSION Washington, D.C. 20549 AMENDMENT NO. 2 to FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES AC Table of Contents As filed with the Securities and Exchange Commission on April 1 5 , 2024 Registration No.
April 15, 2024	EX-99.6	Consent of Stefan Vitorovic to serve as a director of AVROBIO, Inc., to be renamed “Tectonic Therapeutic, Inc.” Exhibit 99.6 Consent to be Named as a Director In connection with the filing by AVROBIO, Inc. (the “Company”) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments a
April 15, 2024	EX-10.43	Offer Letter dated June 16, 2021, by and between Tectonic Therapeutic, Inc. and Marcella Ruddy. Exhibit 10.43 Date: June 16, 2021 Name: Marcie Ruddy Address: Dear Marcie, It is with great pleasure that I am inviting you to join our team at Tectonic Therapeutic, Inc. (the “Company”). Your position will be that of Chief Medical Officer, reporting to me, the President and Chief Executive Officer. Effective Date: The effective date of employment as an exempt, regular, full-time employee will be
April 15, 2024	EX-10.44	Offer Letter dated July 29, 2019, by and between Tectonic Therapeutic, Inc. and Christian Cortis. Exhibit 10.44 July 29, 2019 Christian Cortis, Ph.D. 1 Sylvan Road Wellesley, MA 02481 Email: Re: Offer of Employment Dear Dr. Cortis: I am pleased to offer you a position with Tectonic Therapeutic, Inc. (the “Company”), as its Interim CEO in the Company’s Boston, MA office (address TBD). As we have discussed, it is anticipated that your tile and role may change to another C-level position. If you
April 15, 2024	CORRESP	***** Goodwin Procter LLP 100 Northern Avenue Boston, Massachusetts 02210 VIA EDGAR April 15, 2024 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
April 4, 2024	425	Filed by AVROBIO, Inc. 425 Filed by AVROBIO, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: AVROBIO, Inc. Commission File No.: 001-38537 Date: April 4, 2024 This filing relates to the proposed transaction pursuant to the terms of that certain Agreement and Plan of Merger and Reorganization, dated as of January 30,
March 26, 2024	EX-FILING FEES	Filing fee table. Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) AVROBIO, INC. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry
March 26, 2024	EX-10.38	Master Contract Services Agreement, dated February 16, 2022, by and between Tectonic Therapeutic, Inc. and ITR LABORATORIES CANADA INC. Exhibit 10.38 “CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE TECTONIC THERAPEUTIC, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT TECTONIC THERAPEUTIC, INC. TREATS AS PRIVATE OR CONFIDENTIAL.” MASTER CONTRACT SERVICES AGREEMENT THIS MASTER CONTRACT SERVICES AGREEMENT (together with Appendix A and any Statem
March 26, 2024	EX-10.35	License Agreement, dated February 10, 2022, by and between Tectonic Therapeutic, Inc. and President and Fellows of Harvard College. Exhibit 10.35 “CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE TECTONIC THERAPEUTIC, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT TECTONIC THERAPEUTIC, INC. TREATS AS PRIVATE OR CONFIDENTIAL.” LICENSE AGREEMENT This License Agreement (this “Agreement”) is entered into as of this 10th day of February, 2022 (
March 26, 2024	EX-10.36	Master Agreement for Early Phase Clinical Services, dated October 23, 2023, by and between Tectonic Therapeutic, Inc. and ARENSIA Exploratory Medicine GmbH. Exhibit 10.36 “CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE TECTONIC THERAPEUTIC, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT TECTONIC THERAPEUTIC, INC. TREATS AS PRIVATE OR CONFIDENTIAL.” Master Agreement for Early Phase Clinical Services This Master Agreement for Early Phase Clinical Services (the “Ag
March 26, 2024	EX-10.37	Master Contract Services Agreement, dated October 17, 2023, by and between Tectonic Therapeutic, Inc. and QPS Holdings, LLC. Exhibit 10.37 “CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE TECTONIC THERAPEUTIC, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT TECTONIC THERAPEUTIC, INC. TREATS AS PRIVATE OR CONFIDENTIAL.” MASTER CONTRACT SERVICES AGREEMENT THIS MASTER CONTRACT SERVICES AGREEMENT (together with Appendix A and any Statem
March 26, 2024	EX-10.39	Development and Manufacturing Services Agreement, dated May 6, 2022, by and between Tectonic Therapeutic, Inc. and WuXi Biologics (Hong Kong) Limited. Exhibit 10.39 “CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE TECTONIC THERAPEUTIC, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT TECTONIC THERAPEUTIC, INC. TREATS AS PRIVATE OR CONFIDENTIAL.” DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT THIS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT is made as o
March 26, 2024	EX-99.10	Consent of Houlihan Lokey Capital, Inc. Exhibit 99.10 CONSENT OF HOULIHAN LOKEY CAPITAL, INC. March 25, 2024 AVROBIO, Inc. 100 Technology Square 6th Floor Cambridge, MA 02139 Attn: Board of Directors RE: Proxy Statement / Prospectus of AVROBIO, Inc. (“AVROBIO”), which forms part of Amendment No. 1 to the Registration Statement on Form S-4 of AVROBIO (the “Registration Statement”). Dear Members of the Board: Reference is made to our opin
March 26, 2024	S-4/A	As filed with the Securities and Exchange Commission on March 25, 2024 Registration No. 333-277048 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 to FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF Table of Contents As filed with the Securities and Exchange Commission on March 25, 2024 Registration No.
March 26, 2024	EX-21.1	List of Subsidiaries of Tectonic Therapeutic, Inc. (filed as Exhibit 21.1 to AVROBIO, Inc.’s Amendment No. 1 to the Registration Statement on Form S-4 filed on March 26, 2024 (File No. 333-277048) and incorporated herein by reference). Exhibit 21.1 List of Subsidiaries of Tectonic Therapeutic, Inc. Tectonic Therapeutic Pty Ltd. (Australia) Tectonic Therapeutic Securities Corp. (Massachusetts)
March 26, 2024	EX-10.40	Master Clinical Contract Services Agreement, dated March 6, 2023, by and between Tectonic Therapeutic, Inc. and Novotech (Australia) Pty Limited CAN. Exhibit 10.40 “CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE TECTONIC THERAPEUTIC, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT TECTONIC THERAPEUTIC, INC. TREATS AS PRIVATE OR CONFIDENTIAL.” MASTER CLINICAL CONTRACT SERVICES AGREEMENT THIS MASTER CLINICAL CONTRACT SERVICES AGREEMENT (together with Appendi
March 25, 2024	CORRESP	***** Goodwin Procter LLP 100 Northern Avenue Boston, Massachusetts 02210 VIA EDGAR March 25, 2024 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
March 14, 2024	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of incorporation or organization AVROBIO Inc. Ontario, Canada AVROBIO Australia Pty Ltd Australia AVROBIO Securities Corporation Massachusetts
March 14, 2024	EX-97.1	Compensation Recovery (Clawback) Policy adopted October 5, 2023 Exhibit 97.1 avrobio, inc. COMPENSATION RECOVERY POLICY Adopted as of October 5, 2023 AVROBIO, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) in
March 14, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38537 AVROBIO, INC. (Exa
February 23, 2024	EX-1	JOINT FILING AGREEMENT EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the shares of common stock, par value $0.
February 14, 2024	EX-10.43	2019 Equity Incentive Plan of Tectonic Therapeutic, Inc., and form of award agreements thereunder. Exhibit 10.43 TECTONIC THERAPEUTIC, INC. AMENDMENT TO 2019 EQUITY INCENTIVE PLAN This Amendment to the Tectonic Therapeutic, Inc. 2019 Equity Incentive Plan (this “Amendment”) is dated March 31, 2021 and amends the Tectonic Therapeutic, Inc. 2019 Equity Incentive Plan (as amended to date, the “Plan”). Capitalized words used but not defined herein shall have the meaning given to them in the Plan. 1
February 14, 2024	EX-10.21	Employment Agreement, by and between AVROBIO, Inc. and Azadeh Golipour, dated January 26, 2022. Exhibit 10.21 AVROBIO, INC. EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 26th day of January 2022 (the “Effective Date”), between AVROBIO, Inc., a Delaware corporation (the “Company”), and Azadeh Golipour (the “Executive”). WHEREAS, the Executive is currently employed by the Company pursuant to that certain offer letter dated as of December 22, 2021 (the “Offer Le
February 14, 2024	EX-10.22	Employee Relocation and Transition Benefits Agreement, by and between AVROBIO, Inc. and Azadeh Golipour, dated January 31, 2022. Exhibit 10.22 EMPLOYEE RELOCATION AND TRANSITION BENEFITS AGREEMENT This Employee Relocation and Transition Benefits Agreement (“Agreement”) is entered into as of 31st January 2022 by and between Azadeh Golipour, PhD (“Employee”) and AVROBIO, Inc. 1. Repayment Agreement. Reference is made to that certain Employment Agreement by and between the Company and Employee, dated as of January 26, 2022 (th
February 14, 2024	EX-FILING FEES	Filing fee table. Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) AVROBIO, INC. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry
February 14, 2024	EX-10.41	Consulting Agreement, dated September 25, 2019, by and between Tectonic Therapeutic, Inc. and Andrew Kruse. Exhibit 10.41 TECTONIC THERAPEUTIC, INC. CONSULTING AGREEMENT Effective Date: Sep 25, 2019 This Consulting Agreement (the “Agreement”) is made as of the Effective Date set forth above by and between Tectonic Therapeutic, Inc., a Delaware corporation (“Client”) and the consultant named on the signature page hereto (“Consultant”). 1. Engagement of Services. Client may issue Project Assignments to Co
February 14, 2024	EX-10.42	Tectonic Therapeutic, Inc. 2019 Equity Incentive Plan, and form of award agreements thereunder. Exhibit 10.42 TECTONIC THERAPEUTIC, INC. 2019 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: June 5, 2019 APPROVED BY THE STOCKHOLDERS: June 5, 2019 TERMINATION DATE: June 4, 2029 1. General. (a) Eligible Stock Award Recipients. Employees, Directors and Consultants are eligible to receive Stock Awards. (b) Available Stock Awards. The Plan provides for the grant of the following types of
February 14, 2024	S-4	As filed with the Securities and Exchange Commission on February 1 4 , 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AVROBIO, INC Table of Contents As filed with the Securities and Exchange Commission on February 1 4 , 2024 Registration No.
February 14, 2024	SC 13G	AVRO / AVROBIO, Inc. / Newtyn Management, LLC Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AVROBIO, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05455M100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to
February 14, 2024	EX-99.10	Consent of Houlihan Lokey Capital, Inc. Exhibit 99.10 CONSENT OF HOULIHAN LOKEY CAPITAL, INC. February 14, 2024 AVROBIO, Inc. 100 Technology Square 6th Floor Cambridge, MA 02139 Attn: Board of Directors RE: Proxy Statement / Prospectus of AVROBIO, Inc. (“AVROBIO”), which forms part of the Registration Statement on Form S-4 of AVROBIO (the “Registration Statement”). Dear Members of the Board: Reference is made to our opinion letter (“opi
February 14, 2024	EX-3.1	Certificate of Incorporation of Tectonic Therapeutic, Inc., as currently in effect. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TECTONIC THERAPEUTIC, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Tectonic Therapeutic, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. T
February 14, 2024	EX-21.1	List of Subsidiaries of Tectonic Therapeutic, Inc. Exhibit 21.1 List of Subsidiaries of Tectonic Therapeutic, Inc. Tectonic Therapeutic Pty Ltd.
February 14, 2024	EX-3.2	Bylaws of Tectonic Therapeutic, Inc., as currently in effect. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF TECTONIC THERAPEUTIC, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware is 874 Walker Road, Suite C, City of Dover, County of Kent, 19904 or in such other location as the Board of Directors of the corporation (the “Board of Directors”) may from time to time deter
February 14, 2024	SC 13G/A	AVRO / AVROBIO, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 o111243sc13ga1.htm AMENDMENT NO. 1 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Avrobio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05455M100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropria
February 13, 2024	SC 13G/A	AVRO / AVROBIO, Inc. / GMT CAPITAL CORP - AMENDMENT TO FORM SC 13G Passive Investment SC 13G/A 1 avrb-sc13ga123123.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Avrobio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05455M100 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropria
February 7, 2024	SC 13G/A	AVRO / AVROBIO, Inc. / BML Investment Partners, L.P. Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 1 )* AVROBIO, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05455M100 (CUSIP Number) Decenber 31, 2023 (Dat
January 30, 2024	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Num
January 30, 2024	425	AVROBIO and Tectonic Therapeutic AVROBIO and Tectonic Therapeutic Merger Agreement Conference Call January 30, 2024 Filed by AVROBIO, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: AVROBIO, Inc. Commission File No.: 001-38537 Date: January 30, 2024 This filing relates to the proposed transaction pursuant to the terms of that certain Agreement and Plan of Merger and Reorganization, dated as of January 30,
January 30, 2024	EX-2.1	Agreement and Plan of Merger and Reorganization, dated as of January 30, 2024, by and among AVROBIO, Inc., Alpine Merger Subsidiary, Inc. and Tectonic Therapeutic, Inc. Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: AVROBIO, INC.; ALPINE MERGER SUBSIDIARY, INC.; and TECTONIC THERAPEUTIC, INC. Dated as of January 30, 2024 Table of Contents Section 1. Definitions and Interpretative Provisions 2 1.1 Definitions 2 1.2 Other Definitional and Interpretative Provisions 21 Section 2. Description of Transaction 22 2.1 The Merger 22 2.2 Effects of the M
January 30, 2024	EX-10.4	Form of Contingent Value Rights Agreement Exhibit 10.4 FINAL FORM OF CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of [], 2024, is entered into by and among AVROBIO, Inc., a Delaware corporation (the “Company”) and [], a [] corporation (“Rights Agent”). RECITALS WHEREAS, the Company, Alpine Merger Subsidiary, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“M
January 30, 2024	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 AVROBIO, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Num
January 30, 2024	EX-10.1	Form of Tectonic Support Agreement Exhibit 10.1 FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT This Support Agreement (this “Agreement”) is made and entered into as of January 30, 2024, by and among Tectonic Therapeutic, Inc., a Delaware corporation (the “Company”), AVROBIO, Inc., a Delaware corporation (“Aspen”), and the undersigned stockholder (the “Stockholder”) of the Company. Capitalized terms used herein but not otherwise defi
January 30, 2024	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Num
January 30, 2024	EX-99.1	DISCLAIMER This communication contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding the Exhibit 99.1 Transforming the Discovery of Novel GPCR- Targeted Therapies J A N U A R Y 2 0 2 4 DISCLAIMER This communication contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding the structure, timing and completion of the proposed Merge
January 30, 2024	EX-10.2	Form of AVRO Support Agreement Exhibit 10.2 FORM OF ASPEN STOCKHOLDER SUPPORT AGREEMENT This Support Agreement (this “Agreement”) is made and entered into as of January 30, 2024, by and among Tectonic Therapeutic, Inc., a Delaware corporation (the “Company”), AVROBIO, Inc., a Delaware corporation (“Aspen”), and the undersigned stockholder (the “Stockholder”) of Aspen. Capitalized terms used herein but not otherwise defined shal
January 30, 2024	EX-10.3	Form of Lock-Up Agreement Exhibit 10.3 FORM OF LOCK-UP AGREEMENT [], 2024 AVROBIO, Inc. 100 Technology Square, 6th Floor Cambridge, Massachusetts 02139 Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that AVROBIO, Inc., a Delaware corporation (“Aspen”), is entering into an Agreement and Plan of Merger, dated as of January 30, 2024 (as the same may be amended
January 30, 2024	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 AVROBIO, INC. (E 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File
January 30, 2024	EX-99.1	AVROBIO and Tectonic Therapeutic Announce Merger Combined company to be Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Tectonic’s novel GPCR-targeted therapeutic proteins $130.7 million in private financing commitments w Exhibit 99.1 AVROBIO and Tectonic Therapeutic Announce Merger Combined company to be Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Tectonic’s novel GPCR-targeted therapeutic proteins $130.7 million in private financing commitments with new and existing leading life sciences investors in connection with merger Combined company expected to have approximately $165 milli
January 24, 2024	SC 13G/A	AVRO / AVROBIO, Inc. / Farallon Capital Partners, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
November 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38537 AVROBIO, INC.
November 3, 2023	RW	AVROBIO, Inc. 100 Technology Square Sixth Floor Cambridge, MA 02139 AVROBIO, Inc. 100 Technology Square Sixth Floor Cambridge, MA 02139 November 3, 2023 Via EDGAR Transmission Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: AVROBIO, Inc. – Request for Withdrawal of Registration Statement on Form S-3 (File No. 333-268255) Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act o
August 10, 2023	EX-10.3	Executive Retention Payment Agreement, by and between the Registrant and Azadeh Golipour dated June 26, 2023 EXHIBIT 10.3 AVROBIO, INC. EXECUTIVE RETENTION PAYMENT AGREEMENT This Executive Retention Payment Agreement (“Agreement”) is made as of the 26th day of June, 2023, between AVROBIO, Inc., a Delaware corporation (the “Company”), and Azadeh Golipour (the “Executive”). WHEREAS, the Executive’s continued service and dedication to the Company is highly valued by the Company; and WHEREAS, to incentivize
August 10, 2023	EX-10.1	Executive Retention Payment Agreement, by and between the Registrant and Erik Ostrowski dated June 26, 2023 EXHIBIT 10.1 AVROBIO, INC. EXECUTIVE RETENTION PAYMENT AGREEMENT This Executive Retention Payment Agreement (“Agreement”) is made as of the 26th day of June, 2023, between AVROBIO, Inc., a Delaware corporation (the “Company”), and Erik Ostrowski (the “Executive”). WHEREAS, the Executive’s continued service and dedication to the Company is highly valued by the Company; and WHEREAS, to incentivize t
August 10, 2023	EX-10.4	Executive Retention Payment Agreement, by and between the Registrant and Essra Ridha dated June 26, 2023 EXHIBIT 10.4 AVROBIO, INC. EXECUTIVE RETENTION PAYMENT AGREEMENT This Executive Retention Payment Agreement (“Agreement”) is made as of the 26th day of June, 2023, between AVROBIO, Inc., a Delaware corporation (the “Company”), and Essra Ridha (the “Executive”). WHEREAS, the Executive’s continued service and dedication to the Company is highly valued by the Company; and WHEREAS, to incentivize the
August 10, 2023	EX-2.1	Asset Purchase Agreement by and among Novartis Pharma AG, Novartis Pharmaceuticals Corporation and AVROBIO, Inc., dated May 19, 2023 (filed as Exhibit 2.1 to AVROBIO, Inc.’s Quarterly Report on Form 10-Q filed on August 10, 2023 (File No. 001-38537) and incorporated herein by reference). EXHIBIT 2.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THIS REDACTED INFORMATION HAS BEEN MARKED IN THIS EXHIBIT WITH THREE ASTERISKS [***]. ASSET PURCHASE AGREEMENT by and among NOVARTIS PHARMA AG, NOVARTIS PHARMACEUTICALS CORPORATION and, AVROBIO, INC. Dated as of May
August 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38537 AVROBIO, INC.
August 10, 2023	EX-10.2	Executive Retention Payment Agreement, by and between the Registrant and Steven Avruch dated June 26, 2023 EXHIBIT 10.2 AVROBIO, INC. EXECUTIVE RETENTION PAYMENT AGREEMENT This Executive Retention Payment Agreement (“Agreement”) is made as of the 26th day of June, 2023, between AVROBIO, Inc., a Delaware corporation (the “Company”), and Steven Avruch (the “Executive”). WHEREAS, the Executive’s continued service and dedication to the Company is highly valued by the Company; and WHEREAS, to incentivize th
July 24, 2023	SC 13G	AVRO / AvroBio Inc / BML Investment Partners, L.P. - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* AVROBIO, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05455M100 (CUSIP Number) July 13, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
July 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2023 AVROBIO, INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2023 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Number)
July 12, 2023	EX-99.1	AVROBIO to Explore Strategic Alternatives Exhibit 99.1 AVROBIO to Explore Strategic Alternatives CAMBRIDGE, Mass.-(BUSINESS WIRE)—July 12, 2023 - AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. AVROBIO has made the determina
June 14, 2023	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2023 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Com
June 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 AVROBIO, INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Number
June 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 AVROBIO, INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Number)
June 12, 2023	EX-99.1	UNAUDITED PRO FORMA FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA FINANCIAL INFORMATION On May 19, 2023, AVROBIO, Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Novartis Pharma AG and Novartis Pharmaceuticals Corporation (collectively, the “Purchaser”), providing for the sale of the Company’s cystinosis gene therapy program (designated AVR-RD-04) and al
June 12, 2023	EX-99.2	AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million All-cash transaction, full $87.5 million paid at closing Proceeds expected to extend cash runway into Q4 2024 Exhibit 99.2 AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million All-cash transaction, full $87.5 million paid at closing Proceeds expected to extend cash runway into Q4 2024 CAMBRIDGE, Mass.-(BUSINESS WIRE)—June 12, 2023 - AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced t
June 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 AVROBIO, INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Number)
June 6, 2023	SC 13G	AVRO / AvroBio Inc / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
June 6, 2023	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of AVROBIO, Inc. and further agree to the filing of this agreement as an exhibit thereto. In a
May 22, 2023	EX-99.1	AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million EX-99.1 2 ny20009215x1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million All-cash transaction, with full $87.5 million to be paid at closing Proceeds expected to extend cash runway into Q4 2024 CAMBRIDGE, Mass., May 22, 2023 - AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people fr
May 22, 2023	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2023 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Number)
May 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 AVROBIO, INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Number)
May 18, 2023	EX-99.1	AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting All patients remain off oral cysteamine up to 36 months post gene therapy Sustained engraftment and durable Exhibit 99.1 AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting All patients remain off oral cysteamine up to 36 months post gene therapy Sustained engraftment and durable reduction in leukocyte cystine levels across all patients Received positive regulatory feedback from US and UK agencies CAMBRIDGE, Mass.—
May 18, 2023	EX-99.2	ASGCT 2023 cystinosis update Exhibit 99.2 ASGCT 2023 cystinosis update Disclaimer 2 This presentation has been prepared by AVROBIO, Inc. (“AVROBIO”) for informational purposes only and not for any other purpose. Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys, and other data obtained from third-party sources and AVR
May 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 AVROBIO, INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Number)
May 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38537 AVROBIO, INC.
May 11, 2023	EX-99.1	AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update On track to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Plan to provid Exhibit 99.1 AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update On track to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Plan to provide clinical and regulatory updates on cystinosis program in conjunction with ASGCT annual meeting in May 2023; plan to initiate late-stage
May 1, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of
May 1, 2023	EX-99.1	AVROBIO Announces Leadership Transition Current CFO Erik Ostrowski named interim CEO, replacing Founding President and CEO Geoff MacKay Exhibit 99.1 AVROBIO Announces Leadership Transition Current CFO Erik Ostrowski named interim CEO, replacing Founding President and CEO Geoff MacKay Cambridge, Mass. – May 1, 2023 – AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced the appointment of Erik Ostrowski as interim Chief Executive Office
May 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2023 AVROBIO, INC. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2023 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Numbe
March 23, 2023	EX-99.1	AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update Following positive regulatory feedback, plan to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half Exhibit 99.1 AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update Following positive regulatory feedback, plan to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Patient dosing completed in collaborator-sponsored Phase 1/2 clinical trial for cystinosis; plan t
March 23, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38537 AVROBIO, INC. (Exa
March 23, 2023	EX-21	List of Subsidiaries of AVROBIO, Inc. (filed as Exhibit 21.1 to AVROBIO, Inc.’s Annual Report on Form 10-K filed on March 14, 2024 (File No. 001-38537) and incorporated herein by reference). Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of incorporation or organization AVROBIO Inc. Ontario, Canada AVROBIO Australia Pty Ltd Australia AVROBIO Securities Corporation Massachusetts
March 23, 2023	S-8	As filed with the Securities and Exchange Commission on March 23, 2023 S-8 1 brhc10050092s8.htm S-8 As filed with the Securities and Exchange Commission on March 23, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 81-0710585 (State or other jurisdiction of incorporation or org
March 23, 2023	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) AVROBIO, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offer Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) AVROBIO, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.0001 per sha
March 23, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Numbe
February 27, 2023	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Nu
February 17, 2023	SC 13G	AVRO / Avrobio Inc / Farallon Capital Partners, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 8, 2023	SC 13G/A	AVRO / Avrobio Inc / K2 PRINCIPAL FUND, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A (Rule 13d-102) Amendment No. 1 Under the Securities Exchange Act of 1934 AVROBIO INC (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 05455M100 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate
January 19, 2023	SC 13G/A	AVRO / Avrobio Inc / GMT CAPITAL CORP - SCHEDULE 13G - AVROBIO, INC. Passive Investment SC 13G/A 1 eps8864avro.htm SCHEDULE 13G - AVROBIO, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Avrobio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05455M100 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate
December 7, 2022	EX-99.2	FDA: Food and Drug Administration; 2H: Se cond Half THANK YOU Exhibit 99.2 CO NF I DE NT I AL Arianna living with Gaucher disease type 3 Disclaimer 2 This presentation has been prepared by AVROBIO, Inc. (“AVROBIO”) for informational purposes only and not for any other purpose. Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys, and other data obtained
December 7, 2022	EX-99.1	AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy New compelling clinical data from first-ever Gaucher disease type 3 (GD3) patient and four Gauch Exhibit 99.1 AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy New compelling clinical data from first-ever Gaucher disease type 3 (GD3) patient and four Gaucher disease type 1 (GD1) patients dosed with investigational AVR-RD-02 Data from first pediatric GD3 patient, the more severe, progressive
December 7, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Num
November 8, 2022	EX-99.1	AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update Patient dosing completed in collaborator-sponsored Phase 1/2 clinical trial for cystinosis Rare pediatric disease designations received for Gaucher disease and cystinos Exhibit 99.1 AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update Patient dosing completed in collaborator-sponsored Phase 1/2 clinical trial for cystinosis Rare pediatric disease designations received for Gaucher disease and cystinosis investigational gene therapies Comprehensive Gaucher disease program update planned for Wednesday, Dec. 7 CAMBRIDGE, Mass., Nov. 8, 20
November 8, 2022	EX-FILING FEES	Calculation of Filing Fee Table (Form Type) AVROBIO, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Table S-3 (Form Type) AVROBIO, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (3) Fee Rate Amount of Registrat
November 8, 2022	10-Q	[ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q [ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38537 AVROBIO, INC.
November 8, 2022	EX-4.4	AVROBIO, INC., Dated as of [•], 20[•] Senior Debt Securities TABLE OF CONTENTS1 Exhibit 4.4 AVROBIO, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20[?] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 Section
November 8, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 AVROBIO, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Num
November 8, 2022	S-3	As filed with the Securities and Exchange Commission on November 8, 2022. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 8, 2022.
November 8, 2022	EX-1.2	$50,000,000 COMMON STOCK SALES AGREEMENT Exhibit 1.2 AVROBIO, INC. $50,000,000 COMMON STOCK SALES AGREEMENT November 8, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: AVROBIO, Inc. (the ?Company?) confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Agreement
November 8, 2022	EX-4.5	AVROBIO, INC., Dated as of [•], 20[•] Subordinated Debt Securities TABLE OF CONTENTS1 Exhibit 4.5 AVROBIO, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20[?] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 S
October 7, 2022	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2022 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Numb
August 9, 2022	S-8	As filed with the Securities and Exchange Commission on August 9, 2022 As filed with the Securities and Exchange Commission on August 9, 2022 Registration No.
August 9, 2022	EX-10.3	Amended and Restated Master Services Agreement, by and between AVROBIO, Inc. and Miltenyi Biotec, Inc., dated November 20, 2021 (filed as Exhibit 10.3 to AVROBIO, Inc.’s Quarterly Report on Form 10-Q filed on August 9, 2022 (File No. 001-38537) and incorporated herein by reference). EXHIBIT 10.3 Certain identified information has been excluded from this exhibit because it is both not material and is of the type that the registrant treats as private or confidential. This redacted information has been marked in this exhibit with three asterisks [***]. AMENDED AND RESTATED MASTER SERVICES AGREEMENT for Custom Ex Vivo Cellular Manufacturing Services THIS AMENDED AND RESTATED MAST
August 9, 2022	EX-99.1	AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update Presented positive data from first five patients in Phase 1/2 cystinosis trial1 showing systemic gene therapy effect at the American Society of Gene and Cell Therapy A Exhibit 99.1 AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update Presented positive data from first five patients in Phase 1/2 cystinosis trial1 showing systemic gene therapy effect at the American Society of Gene and Cell Therapy Annual Meeting; all five patients remain off oral cysteamine Comprehensive Gaucher disease franchise update planned for Q4 2022 Regulatory
August 9, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Numbe
August 9, 2022	10-Q	[ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q [ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38537 AVROBIO, INC.
August 9, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table S-8 (Form Type) AVROBIO, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.0001 per shar
August 1, 2022	SC 13G	AVRO / Avrobio Inc / K2 PRINCIPAL FUND, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Under the Securities Exchange Act of 1934 AVROBIO, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05455M100 (CUSIP Number) July 28, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed
June 29, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2022 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Number
June 29, 2022	EX-99.1	Disclaimer This presentation has been prepared by AVROBIO, Inc. (“AVROBIO”) for informational purposes only and not for any other purpose. Certain information contained in this presentation and statements made orally during this presentation relate t JUNE 2022 Corporate Presentation Exhibit 99.1 Disclaimer This presentation has been prepared by AVROBIO, Inc. (?AVROBIO?) for informational purposes only and not for any other purpose. Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and AV
June 10, 2022	8-K	Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Number)
June 10, 2022	EX-10.1	Second Amendment to the AVROBIO, Inc. 2018 Stock Option and Incentive Plan (filed as Exhibit 10.1 to AVROBIO, Inc.’s Current Report on Form 8-K filed on June 10, 2022 (File No. 001-38537) and incorporated herein by reference). Exhibit 10.1 SECOND AMENDMENT TO THE AVROBIO, INC. 2018 STOCK OPTION AND INCENTIVE PLAN This Second Amendment (this ?Amendment?) to the AVROBIO, Inc. 2018 Stock Option and Incentive Plan (the ?Plan?), of AVROBIO, Inc. (the ?Company?) is effective as of the date of approval by the Company?s stockholders (the ?Effective Date?). Capitalized terms used herein and not otherwise defined shall have the m
May 24, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Number)
May 24, 2022	EX-99.1	Disclaimer This presentation has been prepared by AVROBIO, Inc. (“AVROBIO”) for informational purposes only and not for any other purpose. Certain information contained in this presentation and statements made orally during this presentation relate t EX-99.1 MAY 2022 Corporate Presentation Exhibit 99.1 Disclaimer This presentation has been prepared by AVROBIO, Inc. (“AVROBIO”) for informational purposes only and not for any other purpose. Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources
May 18, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 AVROBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-38537 81-0710585 (State or other jurisdiction of incorporation) (Commission File Number)
May 18, 2022	EX-99.1	AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) annual meeting Genetically modified hematopoietic stem cells lead to supraphysiological levels of therapeutic protein in a mouse mo Exhibit 99.1 AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) annual meeting Genetically modified hematopoietic stem cells lead to supraphysiological levels of therapeutic protein in a mouse model of Pompe disease sustained at eight months after administration Substantial reduction in glycogen observed across cardiac and skeleta

AVRO / AVROBIO, Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

الإحصائيات الأساسية

SEC Filings

SEC Filings (Chronological Order)